Abstract
ATL1102, an antisense drug which targets CD49d, an immune cell adhesion, survival and activation molecule, is being evaluated in an open label study in nine adolescent non-ambulant patients with Duchenne muscular dystrophy (DMD) ACTRN12618000970246. The nine patients, 12 to 18 years old (mean 14.9 (SD 2.1) years), were dosed with ATL1102 once weekly at 25mg s.c. for 24 weeks and were assessed using the Performance of the Upper Limb Module (PUL2.0). The data of the ATL1102-treated patients (8 of 9 on corticosteroid) was compared with the 24-week PUL2.0 data of 20 patients (mean age 15.61 (SD 2.02) years; 19 on corticosteroid) from a natural history database of patients in Rome, Italy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
